Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.

Autor:	Wong, Ian TY, Shojania, Kam, Dutz, Jan, Tsao, Nicole W
Předmět:	THERAPEUTIC use of monoclonal antibodies COMPARATIVE studies DERMATOLOGIC agents INTERLEUKINS RESEARCH methodology MEDICAL cooperation MONOCLONAL antibodies PSORIASIS QUALITY of life RESEARCH EVALUATION research SEVERITY of illness index CHEMICAL inhibitors PHARMACODYNAMICS ECONOMICS THERAPEUTICS
Zdroj:	Expert Review of Pharmacoeconomics & Outcomes Research; Apr2016, Vol. 16 Issue 2, p153-166, 14p
Abstrakt:	Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in patients that had limited benefit from non-biologic systemic therapies and phototherapy. Despite standard-of-care systemic therapies being more likely to be cost-effective at this time, a Canadian cost-utility analysis found secukinumab to display benefit in quality-of-life gains in moderate-to-severe plaque psoriasis patients, and greater cost-effectiveness when compared to other biologic systemic therapies. Determination of the true economic value of secukinumab amongst the available therapies for moderate-to-severe plaque psoriasis will require continued economic evaluation. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu